Petros Pharmaceuticals, Inc.
PTPIOther · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | $5.1M | $5.8M | $6.0M | $7.8M | $9.6M |
| Operating income | −$4.6M | −$17.7M | −$13.6M | −$19.9M | −$18.0M | −$17.3M |
| Net income | $1.9M | −$14.3M | −$8.2M | −$20.0M | −$9.0M | −$20.6M |
| Total assets | $5.2M | $10.6M | $33.8M | $32.4M | $67.4M | $69.9M |
| Total liabilities | $2.3M | $18.1M | $21.3M | $15.7M | $31.8M | $52.4M |
| Equity | $2.9M | −$7.5M | $12.1M | $16.7M | $35.5M | $17.5M |
| EPS (diluted) | $-1.56 | $-3.34 | $-6.35 | $-9.68 | $-8.25 | $-3.85 |
| Shares out. | 53.5M | 6.9M | 2.1M | 20.7M | 2.1M | 9.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 66.7%
- Return on assets
- 37.1%
- Return on capital (ROCE)
- −161.7%
- Liabilities / assets
- 44.4%
- Debt / equity
- 0.80×
- Book value / share
- $0.05
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -71.34distress
- Accruals / assets
- 167.5%high accruals
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Boctor FadyOfficer — See Remarks | Jan 2, 2026 | Grant | 500,000 | $0.00 |
| Silverman JoshuaDirector | Jan 2, 2026 | Grant | 4.4M | $0.00 |
| Walker Wayne RemellDirector | Jan 2, 2026 | Grant | 500,000 | $0.00 |
| Bernstein BruceDirector | Jan 2, 2026 | Grant | 1.9M | $0.00 |
| Walker Wayne RemellDirector | Feb 19, 2025 | Grant | 150,000 | $0.00 |
| Arnold MitchellOfficer — See Remarks | Feb 19, 2025 | Grant | 150,000 | $0.00 |
| Silverman JoshuaDirector | Feb 19, 2025 | Grant | 1.0M | $0.00 |
| Boctor FadyOfficer — See Remarks | Feb 19, 2025 | Grant | 450,000 | $0.00 |
| Bernstein BruceDirector | Feb 19, 2025 | Grant | 300,000 | $0.00 |
| Boctor FadyOfficer — See Remarks | Dec 21, 2023 | Grant | 49,645 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 754 | 1.0 | -98.9% |
| Apr 30, 2026 | 67,570 | 1.0 | +8861.5% |
| Apr 15, 2026 | 754 | 1.0 | 0.0% |
| Mar 31, 2026 | 754 | 1.0 | -0.3% |
| Mar 13, 2026 | 756 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeJan 2, 2026
- Delisting / listing-standard noticeNov 7, 2025
- Changed auditorSep 5, 2025
- Regulation FD disclosureJun 20, 2025
- Delisting / listing-standard noticeMay 21, 2025
- Delisting / listing-standard notice · Modified shareholder rights · Amended charter or bylawsMay 2, 2025
- Delisting / listing-standard notice · Modified shareholder rights · Director / officer change · Amended charter or bylaws · Shareholder voteApr 11, 2025
- Changed auditorApr 9, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QMay 13, 2026
- 10-KApr 15, 2026
- NT 10-KMar 31, 2026
- SCHEDULE 13G/AFeb 17, 2026
- 4OWNERSHIP DOCUMENTJan 6, 2026
- 4OWNERSHIP DOCUMENTJan 2, 2026
- 8-KFORM 8-KJan 2, 2026
- 4OWNERSHIP DOCUMENTJan 2, 2026
- 4OWNERSHIP DOCUMENTJan 2, 2026
- 25-NSENov 20, 2025
- 10-QNov 13, 2025
- 8-KFORM 8-KNov 7, 2025
- 8-KFORM 8-KSep 5, 2025
- SCHEDULE 13G/AAug 15, 2025
- 10-QAug 14, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.